共 50 条
Anthacyclines in non-small cell lung cancer
被引:0
|作者:
Pronzato, P
[1
]
Vigani, A
Tognoni, A
Vaira, F
Canessa, P
机构:
[1] Osped S Angrea, Dept Med Oncol, I-19100 La Spezia, Italy
[2] Osped S Andrea, Dept Pneumol, I-19100 La Spezia, Italy
来源:
关键词:
non-small cell lung cancer;
chemotherapy;
anthracyclines;
D O I:
暂无
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
The literature concerning the use of anthracyclines in the treatment of non-small cell lung cancer (NSCLC) is reviewed here. Overall. the activity of doxorubicin (DOXO) is unsatisfactory, whereas, the analogous epidoxorubicin (EPI) yields a 30% response rate (RR) when administered at intermediate-high doses. All active drugs, including EPI. should be considered to design the most active combination. Mainly. in the setting. in which an objective response is very important. for instance the neo-adjuvant pre-operatory setting. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:S57 / S59
页数:3
相关论文